Advertisement

Cardiovascular Health by Graves’ Disease Management Modality – Surgery Versus Radioactive Iodine Versus Antithyroid Medications: A Network Meta-Analysis

Published:November 21, 2022DOI:https://doi.org/10.1016/j.jss.2022.10.043

      Abstract

      Introduction

      Graves' disease is an autoimmune disorder of the thyroid gland associated with the overproduction of thyroid hormones. Excess secretion of thyroid hormones leads to cardiovascular consequences. Treatment options include antithyroid medications (ATM), radioactive iodine (RAI) ablation, and total thyroidectomy. We examined the cardiovascular outcomes following Graves’ disease management modality.

      Methods

      A systematic search was performed up to September 22nd, 2021, using PubMed, EMBASE, and Web of Science databases. We conducted a network meta-analysis analyzing cardiovascular outcomes of interest, including congestive heart failure (CHF), arrhythmia, atrial fibrillation (AF), and hypertension.

      Results

      Three studies were included in this analysis totaling 6700 patients with Graves’ disease, of which 74% were female. The mean age was 44.34 y. When compared to pretreatment, management options lowered the risk of maintaining arrhythmia 81% with surgery (relative risk [RR] = 0.19; 95% confidence interval [CI] = 0.12 to 0.31), 67% with ATM (RR = 0.33; 95% CI = 0.23 to 0.49), and 50% with RAI (RR = 0.50; 95% CI = 0.13 to 1.95). Risk of maintaining CHF was reduced 80% with surgery (RR = 0.20; 95% CI = 0.08 to 0.49), 41% with ATM (RR = 0.59; 95%CI = 0.52 to 0.67), and only 7% with RAI (RR = 0.93; 95%CI = 0.68 to 1.26). Treatment-ranking analysis found all parameters, including CHF, arrhythmia, AF, and hypertension, to be in favor of surgical treatment over medical treatment and RAI ablation.

      Conclusions

      This is the first network meta-analysis analyzing the cardiovascular outcomes in Graves’ disease patients by treatment option. Our study demonstrated that surgery is superior to RAI and medical treatment.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Surgical Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Wang C.
        • Crapo L.M.
        The epidemiology of thyroid disease and implications for screening.
        Endocrinol Metab Clin. 1997; 26: 189-218
        • Bülow Pedersen I.
        • Laurberg P.
        • Knudsen N.
        • et al.
        Increase in incidence of hyperthyroidism predominantly occurs in young people after iodine fortification of salt in Denmark.
        J Clin Endocrinol Metab. 2006; 91: 3830-3834
        • Akram S.
        • Elfenbein D.M.
        • Chen H.
        • Schneider D.F.
        • Sippel R.S.
        Assessing American Thyroid Association guidelines for total thyroidectomy in Graves’ disease.
        J Surg Res. 2020; 245: 64-71
        • Klein I.
        • Ojamaa K.
        Thyroid hormone and the cardiovascular system.
        N Engl J Med. 2001; 344: 501-509
        • Klein I.
        • Danzi S.
        Thyroid disease and the heart.
        Circulation. 2007; 116: 1725-1735
        • Faber J.
        • Selmer C.
        Cardiovascular disease and thyroid function.
        in: Cardiovascular Issues in Endocrinology. 43. Karger Publishers, Basel, Switzerland2014: 45-56
        • Naser J.A.
        • Pislaru S.
        • Stan M.N.
        • Lin G.
        Incidence, risk factors, natural history and outcomes of heart failure in patients with Graves’ disease.
        Heart. 2022; 108: 868-874
        • LIN H.
        • YANG L.
        • KANG J.
        Increased risk of pulmonary embolism among patients with hyperthyroidism: a 5-year follow-up study.
        J Thromb Haemost. 2010; 8: 2176-2181
        • Brandt F.
        • Green A.
        • Hegedüs L.
        • Brix T.H.
        A critical review and meta-analysis of the association between overt hyperthyroidism and mortality.
        Eur J Endocrinol. 2011; 165: 491-497
        • Gibson A.
        • Dave A.
        • Johnson C.
        • Kotwal A.
        • Fingeret A.L.
        Cardiovascular outcomes of thyroidectomy or radioactive iodine ablation for Graves’ disease.
        J Surg Res. 2020; 256: 486-491
        • Franklyn J.A.
        The management of hyperthyroidism.
        N Engl J Med. 1994; 330: 1731-1738
        • Mumtaz M.
        • Lin L.S.
        • Hui K.C.
        • Khir A.S.M.
        Radioiodine I-131 for the therapy of Graves’ disease.
        Malays J Med Sci. 2009; 16: 25
        • Sundaresh V.
        • Brito J.P.
        • Wang Z.
        • et al.
        Comparative effectiveness of therapies for Graves’ hyperthyroidism: a systematic review and network meta-analysis.
        J Clin Endocrinol Metab. 2013; 98: 3671-3677
        • Burch H.B.
        • Cooper D.S.
        Management of Graves disease: a review.
        JAMA. 2015; 314: 2544-2554
        • Husseni M.
        The incidence of hypothyroidism following the radioactive iodine treatment of graves’ disease and the predictive factors influencing its development.
        World J Nucl Med. 2016; 15: 30-37
        • Bonnema S.J.
        • Hegedüs L.
        Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome.
        Endocr Rev. 2012; 33: 920-980
        • Shim S.R.
        • Kitahara C.M.
        • Cha E.S.
        • Kim S.J.
        • Bang Y.J.
        • Lee W.J.
        Cancer risk after radioactive iodine treatment for hyperthyroidism: a systematic review and meta-analysis.
        JAMA Netw Open. 2021; 4: e2125072
        • Iagaru A.
        • McDougall I.R.
        Treatment of thyrotoxicosis.
        J Nucl Med. 2007; 48: 379-389
        • Liu X.
        • Wong C.K.
        • Chan W.W.
        • et al.
        Outcomes of graves’ disease patients following antithyroid drugs, radioactive iodine, or thyroidectomy as the first-line treatment.
        Ann Surg. 2021; 273: 1197-1206
        • Elnahla A.
        • Attia A.S.
        • Khadra H.S.
        • et al.
        Impact of surgery versus medical management on cardiovascular manifestations in Graves disease.
        Surgery. 2021; 169: 82-86
        • Moher D.
        • Liberati A.
        • Tetzlaff J.
        • Altman D.G.
        • PRISMA Group∗
        Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
        Ann Intern Med. 2009; 151: 264-269
        • Phan K.
        • Tian D.H.
        • Cao C.
        • Black D.
        • Yan T.D.
        Systematic review and meta-analysis: techniques and a guide for the academic surgeon.
        Ann Cardiothorac Surg. 2015; 4: 112
        • White I.R.
        Network meta-analysis.
        Stata J. 2015; 15: 951-985
        • Rücker G.
        • Schwarzer G.
        Reduce dimension or reduce weights? Comparing two approaches to multi-arm studies in network meta-analysis.
        Stat Med. 2014; 33: 4353-4369
        • White I.R.
        • Barrett J.K.
        • Jackson D.
        • Higgins J.P.
        Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression.
        Res Synth Methods. 2012; 3: 111-125
        • Dias S.
        • Welton N.J.
        • Caldwell D.
        • Ades A.E.
        Checking consistency in mixed treatment comparison meta-analysis.
        Stat Med. 2010; 29: 932-944
        • Rücker G.
        • Schwarzer G.
        Ranking treatments in frequentist network meta-analysis works without resampling methods.
        BMC Med Res Methodol. 2015; 15: 1-9
        • bo Yang L.
        • qing Jiang D.
        • bo Qi W.
        • et al.
        Subclinical hyperthyroidism and the risk of cardiovascular events and all-cause mortality: an updated meta-analysis of cohort studies.
        Eur J Endocrinol. 2012; 167: 75
        • Muthukumar S.
        • Ravikumar K.
        • Dhalapathy S.
        • Gomathy T.
        • Umadevi S.
        • Maruthupandian D.
        A prospective comparative study on improvement of hyperthyroid cardiovascular dysfunction in patients undergoing total thyroidectomy versus medical management.
        World J Surg. 2018; 42: 1408-1414
        • Muthukumar S.
        • Sadacharan D.
        • Ravikumar K.
        • Mohanapriya G.
        • Hussain Z.
        • Suresh R.
        A prospective study on cardiovascular dysfunction in patients with hyperthyroidism and its reversal after surgical cure.
        World J Surg. 2016; 40: 622-628
        • Banach M.
        • Misztal M.
        • Goch A.
        • Rysz J.
        • Goch J.H.
        Predictors of atrial fibrillation in patients following isolated surgical revascularization. A metaanalysis of 9 studies with 28 786 patients.
        Arch Med Sci. 2007; 3: 229-239
        • Sawin C.T.
        • Geller A.
        • Wolf P.A.
        • et al.
        Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons.
        N Engl J Med. 1994; 331: 1249-1252
        • Staffurth J.
        • Gibberd M.C.
        • Fui S.
        Arterial embolism in thyrotoxicosis with atrial fibrillation.
        Br Med J. 1977; 2: 688-690
        • Agner T.
        • Almdal T.
        • Thorsteinsson B.
        • Agner E.
        A reevaluation of atrial fibrillation in thyrotoxicosis.
        Dan Med Bull. 1984; 31: 157-159
        • Sjölin G.
        • Holmberg M.
        • Törring O.
        • et al.
        The long-term outcome of treatment for Graves’ hyperthyroidism.
        Thyroid. 2019; 29: 1545-1557
        • Dhaun N.
        • Goddard J.
        • Kohan D.E.
        • Pollock D.M.
        • Schiffrin E.L.
        • Webb D.J.
        Role of endothelin-1 in clinical hypertension: 20 years on.
        Hypertension. 2008; 52: 452-459
        • Vargas-Uricoechea H.
        • Bonelo-Perdomo A.
        • Sierra-Torres C.H.
        Effects of thyroid hormones on the heart.
        Clin Investig Arterioscler. 2014; 26: 296-309
        • Danzi S.
        • Klein I.
        Thyroid disease and the cardiovascular system.
        Endocrinol Metab Clin. 2014; 43: 517-528
        • Osuna P.M.
        • Udovcic M.
        • Sharma M.D.
        Hyperthyroidism and the heart.
        Methodist Debakey Cardiovasc J. 2017; 13: 60
        • Biondi B.
        Heart failure and thyroid dysfunction.
        Eur J Endocrinol. 2012; 167: 609-618
        • RossDouglas S.
        • BurchHenry B.
        • CooperDavid S.
        • et al.
        2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis.
        Thyroid. 2016; 26: 1343-1421
        • Azizi F.
        • Malboosbaf R.
        Long-term antithyroid drug treatment: a systematic review and meta-analysis.
        Thyroid. 2017; 27: 1223-1231
        • Hauch A.
        • Al-Qurayshi Z.
        • Randolph G.
        • Kandil E.
        Total thyroidectomy is associated with increased risk of complications for low-and high-volume surgeons.
        Ann Surg Oncol. 2014; 21: 3844-3852